MedTrace Logo

Radotinib as 3rd or Later Line Therapy in CP-CML

NCT02422719 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2016-05-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether radotinib is effective and safe for patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to prior 2 or more tyrosine kinase inhibitors.

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

Radotinib

Radotinib 400mg bid

Sponsors & Collaborators

  • Ulsan University Hospital

    lead OTHER

Principal Investigators

  • Hawk Kim, M.D., Ph.D. · Ulsan University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02422719 on ClinicalTrials.gov